On October 24, 2023 Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, reported that it will host a virtual key opinion leader event to highlight the prexigebersen program and discuss advances in the treatment landscape for acute myeloid leukemia (AML) (Press release, Bio-Path Holdings, OCT 24, 2023, View Source [SID1234636293]). The conference call will be held on Monday, October 30, 2023 at 9:00 a.m. ET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The event will be hosted by Peter Nielsen, Chief Executive Officer of Bio-Path, and will feature presentations and discussion with:
• Jorge Cortes, M.D., Director, Georgia Cancer Center, Augusta University
• Maro Ohanian, D.O., Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
To access the live conference call, please call (833) 630-1956 (domestic) or (412) 317-1837 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.